Fig. 5 | Scientific Reports

Fig. 5

From: Expression of c-erb-B2 oncoprotein as a neoantigen strategy to repurpose anti-neu antibody therapy in a model of melanoma

Fig. 5

Naïve (wild-type) B16 tumors were inoculated with pLenti6.3 c-erb-B2 to generate c-erb-B2 as a neoantigen target for 7.16.4 in vivo. The addition of 7.16.4 to pLenti6.3 c-erb-B2 resulted in statistically significant decreased tumor growth (A) and improved long-term survival (B), again with 41.2% of mice showing complete clinical response (mice euthanized at day 90). In (A), the bar shows statistical significance between the two groups of particular interest: (1) naïve B16 + pLenti6.3 c-erb-B2 and (2) naïve B16 + pLenti6.3 c-erb-B2 + 7.16.4.

Back to article page